De werkwijze van FAST
FAST richt zich op therapieontwikkeling in de brede zin van de geneesmiddelenwet, inclusief cell-based therapies en gentherapie, waarbij ruimte wordt gegeven aan toekomstige innovaties waar de interventies zich niet enkel richten op een geneesmiddel maar op combinaties van geneesmiddelen (drugs), devices, data en diagnostiek.
Investing in future therapy development
With an extensive network of partners, FAST works on solutions for complex issues in the process of therapy development and makes expertise and advice available within the prioritized focus areas. Social needs and opportunities for the Dutch LSH sector are leading in this.
Support
Supporting innovators in therapy development
Connect
Strengthen connectivity in the ecosystem
Signal
Continuously identifying and addressing bottlenecks and gaps
Strengthen
Through open dialogue about interests of companies and patients
Save the date: RSNN Annual workshop 2022 on 5 September
Jaarbeurs Utrecht